• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ETHZilla Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    12/1/25 4:32:18 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETHZ alert in real time by email
    false 0001690080 0001690080 2025-12-01 2025-12-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported):  December 1, 2025

     

    ETHZilla Corporation

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-38105   90-1890354
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    2875 South Ocean Blvd, Suite 200
    Palm Beach, FL
      33480
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (650) 507-0669

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   ETHZ   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    As previously disclosed in the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2025, ETHZilla Corporation (the “Company”) granted shares of restricted common stock of the Company, par value $0.0001 per share (“Common Stock”) to Mr. McAndrew Rudisill, the Company’s Chairman and Chief Executive Officer (“CEO”), and to each director of the Company (the “Directors”) on November 12, 2025, pursuant to the terms of the 2025 Omnibus Incentive Plan, approved by the Company’s stockholders at a Special Meeting held on October 7, 2025 (the “Awards”).

     

    Following the disclosure of the Awards, the Company received feedback from stockholders expressing concerns regarding the structure of certain of the Awards. The Board of Directors and the Compensation Committee carefully considered this shareholder feedback, together with other relevant factors, and determined to revisit certain equity compensation awards made on November 12, 2025 as specified below.

     

    On December 1, 2025, upon the recommendation of the Compensation Committee, the Board of Directors approved the rescission and cancellation, in their entirety and effective immediately, of the shares of restricted Common Stock previously granted to the CEO and each Director on November 12, 2025. In addition, on December 1, 2025, the CEO and each Director entered into a Restricted Stock Award Rescission Agreement (each a “Rescission Agreement”) with the Company pursuant to which each of them acknowledged and agreed to the rescission and cancellation of the Awards. No consideration was paid in connection with these rescissions, and all such awards have been cancelled. The Company expects that the CEO and each Director will file an updated Form 4 pursuant to Section 16 of the Securities Exchange Act of 1934, as amended. The previously disclosed grant made to John Saunders, who was appointed as Chief Financial Officer of the Company on November 12, 2025 is unaffected.

     

    The Compensation Committee and the Board of Directors will continue to consider appropriate equity compensation awards for the CEO and the Company’s Directors.

     

    Item 9.01 Financial Statements and Exhibits

     

    Exhibit No.   Description
    10.1*   Form of Rescission Agreement
    104   Inline XBRL for the cover page of this Current Report on Form 8-K

     

    *Filed herewith.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: December 1, 2025

     

      ETHZilla Corporation
       
      By:  /s/ McAndrew Rudisill
        Name:  McAndrew Rudisill
        Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $ETHZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ETHZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ETHZ
    SEC Filings

    View All

    ETHZilla Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    12/10/25 4:30:27 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    12/10/25 8:30:53 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    12/10/25 8:01:40 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Director Suckling Andrew P

    4/A - ETHZilla Corp (0001690080) (Issuer)

    12/3/25 7:57:05 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Director New Jason Griffin

    4/A - ETHZilla Corp (0001690080) (Issuer)

    12/3/25 7:56:23 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Director Heter Crystal Jane

    4/A - ETHZilla Corp (0001690080) (Issuer)

    12/3/25 7:55:44 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ETHZilla Announces Plans to Effect Early Redemption of 2028 Convertible Notes to Streamline Capital Structure

    PALM BEACH, Fla., Dec. 10, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company") today announced that it intends to redeem in full its outstanding $516 million in aggregate principal amount of convertible notes due 2028 (the "Convertible Notes") on or by December 30, 2025, at a purchase price of 117% of the outstanding aggregate principal amount of the Convertible Notes, plus all accrued and unpaid interest and any other amounts due thereon. The Company intends to release the restricted cash on hand pledged as collateral to facilitate the redemp

    12/10/25 8:30:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla and Zippy Enter into Definitive Agreements with Plans to Tokenize Manufactured Home Loans On-Chain, ETHZilla Takes 15% Stake in Zippy

    Latest strategic investment further advances ETHZilla's real-world asset strategy, with plans to extend tokenization capabilities to manufactured housing finance PALM BEACH, Fla., Dec. 10, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), a technology company bringing decentralized finance infrastructure to traditional finance, today announced the entry into several agreements with Zippy, Inc. ("Zippy"), a modern, institutionally ready digital lending platform with the goal of bringing manufactured home loans, one of America's most underserved credit markets, on-chain as tokenized real-world assets (RWAs). Under the terms of the agreements, ETHZilla will

    12/10/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Integrates Karus to Power AI-Modeled Auto Loan Tokenization

    Strategic transaction seeks to combine Karus's predictive credit analytics with ETHZilla's blockchain infrastructure to bring real-world credit investments on-chain PALM BEACH, Fla., Dec. 3, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), a technology company bringing decentralized finance infrastructure to traditional finance, today announced the acquisition of a 20% fully-diluted interest in Karus, Inc. ("Karus"), a leading artificial intelligence (AI) platform for auto finance decisioning and portfolio analytics. Pursuant to the transaction, ETHZilla plans to integrate Karus's AI-driven underwriting into its blockchain infrastructure, enabling the to

    12/3/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Leadership Updates

    Live Leadership Updates

    View All

    ETHZilla names John Kristoff as SVP, Corporate Communications and Investor Relations

    PALM BEACH, Fla., Oct. 16, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), a leading technology company connecting traditional finance with decentralized finance, today announced the appointment of John D. Kristoff as Senior Vice President, Corporate Communications and Investor Relations. He will report directly to Chairman and CEO McAndrew Rudisill. In this newly created role, Kristoff will lead ETHZilla's communications and investor relations strategies, shaping the company's narrative and deepening engagement with both the media and investors. He will also play a k

    10/16/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Announces Appointment of Jason New to Board of Directors

    PALM BEACH, Fla., Oct. 8, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), today announced that Jason New, Vice Chairman of Investment Banking at Lazard, has been appointed as a member of its Board of Directors, effective immediately. Mr. New brings more than two decades of experience in global credit, private equity, and alternative investments. He previously co-founded NovaWulf Management, a digital-asset investment and infrastructure platform, and served as Chief Executive Officer of Onex Credit Partners, a $25 billion alternative credi

    10/8/25 7:59:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Financials

    Live finance-specific insights

    View All

    ETHZilla Integrates Karus to Power AI-Modeled Auto Loan Tokenization

    Strategic transaction seeks to combine Karus's predictive credit analytics with ETHZilla's blockchain infrastructure to bring real-world credit investments on-chain PALM BEACH, Fla., Dec. 3, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), a technology company bringing decentralized finance infrastructure to traditional finance, today announced the acquisition of a 20% fully-diluted interest in Karus, Inc. ("Karus"), a leading artificial intelligence (AI) platform for auto finance decisioning and portfolio analytics. Pursuant to the transaction, ETHZilla plans to integrate Karus's AI-driven underwriting into its blockchain infrastructure, enabling the to

    12/3/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Reports Third Quarter 2025 Financial Results

    Company generates $4.1 million in revenue in first six weeks operating as ETHZilla; Accelerates RWA tokenization initiatives PALM BEACH, Fla., Nov. 14, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), a technology company connecting traditional finance and decentralized finance (DeFi), today announced financial results for the third quarter ended September 30, 2025. Management Commentary "This quarter marked a transformative leap for ETHZilla, establishing us as a technology leader in DeFi and positioning us for real-world asset (RWA) toke

    11/14/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care